Orphanet. Duchenne and Becker muscular dystrophy. 2020. https://www.orpha.net/. Accessed 14 Nov 2023.

Kourakis S, Timpani CA, Campelj DG, et al. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J Rare Dis. 2021;16(1):117.

Article  PubMed  PubMed Central  Google Scholar 

Ferizovic N, Summers J, de Zárate IBO, et al. Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE. 2022;17(3): e0265879.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dang UJ, Ziemba M, Clemens PR, et al. Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. Hum Mol Genet. 2020;29(15):2481–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiorillo AA, Tully CB, Damsker JM, et al. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone. Physiol Genomics. 2018;50(9):735–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ReveraGen BioPharma Inc., Santhera Pharmaceuticals. Santhera and ReveraGen announce FDA acceptance of new drug application for vamorolone in Duchenne muscular dystrophy [media release]. 9 Jan 2023. https://www.reveragen.com.

Heier CR, Yu Q, Fiorillo AA, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019;2(1): e201800186.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Wang Y, Gutierrez JS, et al. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 2020;117(39):24285–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol. 2022;79(10):1005–14.

Article  PubMed  PubMed Central  Google Scholar 

Catalyst Pharmaceuticals Inc. Vamorolone: US prescribing information. 2023. https://agamree.com/. Accessed 17 Nov 2023.

Santhera Pharmaceuticals. Santhera receives U.S. FDA approval of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy [media release]. Oct 27 2023. https://www.santhera.com/.

European Medicines Agency. Agamree (vamorolone): CHMP summary of positive opinion. 2023. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/agamree. Accessed 17 Nov 2023.

Santhera Pharmaceuticals Inc. Santhera submits marketing authorization application to the UK MHRA for vamorolone in Duchenne muscular dystrophy [media release]. 2 Mar 2023. https://www.santhera.com.

Santhera Pharmaceuticals, ReveraGen BioPharma Inc. Santhera and ReveraGen announce first participant dosed in FDA-funded phase 2 pilot study with vamorolone in Becker muscular dystrophy [media release]. 22 Aug 2022. https://www.santhera.com.

Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals acquires exclusive North American license for vamorolone for Duchenne muscular dystrophy from Santhera Pharmaceuticals [media release]. 19 Jul 2023. https://www.catalystpharma.com.

Santhera Pharmaceuticals Inc. Santhera grants exclusive North America license for vamorolone to Catalyst Pharmaceuticals in deal valued at up to USD 231 million plus royalties [media release]. 20 Jan 2023. https://www.santhera.com.

Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals to license North American rights to vamorolone for Duchenne muscular dystrophy from Santhera Pharmaceuticals [media release]. 19 Jul 2023. https://www.catalystpharma.com.

Sperogenix Therapeutics. Sperogenix and Santhera entered into exclusive license agreement for vamorolone in rare diseases in the Greater China region [media release]. 4 Jan 2022. https://www.sperogenix.com/.

Santhera Pharmaceuticals. Santhera enters into exclusive license agreement with Sperogenix for vamorolone in rare diseases in the Greater China region [media release]. 4 Jan 2022. https://www.santhera.com.

Actelion Ltd., ReveraGen BioPharma Inc. Actelion obtains an option to in-license vamorolone from ReveraGen [media release]. 3 Nov 2016. https://www.reveragen.com/.

Idorsia Ltd. Idorsia assigns and transfers agreement with ReveraGen to Santhera [media release]. 2 Sep 2020. https://www.idorsia.com/.

Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013;5(10):1569–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conklin LS, Damsker JM, Hoffman EP, et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018;136:140–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffman EP, Riddle V, Siegler MA, et al. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids. 2018;134:43–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCormack NM, Nguyen NY, Tully CB, et al. Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice. iScience. 2023;26(7): 107161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sreetama SC, Chandra G, Van der Meulen JH, et al. Membrane stabilization by modified steroid offers a potential therapy for muscular dystrophy due to dysferlin deficit. Mol Ther. 2018;26(9):2231–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mavroudis PD, van den Anker J, Conklin LS, et al. Population pharmacokinetics of vamorolone (VBP15) in healthy men and boys with Duchenne muscular dystrophy. J Clin Pharmacol. 2019;59(7):979–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leinonen M, Hasham S, Guglieri M, et al. Efficacy and safety of vamorolone during 48-week treatment in patients with Duchenne muscular dystrophy (DMD) in the VBP15-004 study [abstract no. and poster]. In: MDA clinical & scientific conference USA. 2022.

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. 2019;93(13):e1312–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith EC, Conklin LS, Hoffman EP, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17(9): e1003222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mah JK, Clemens PR, Guglieri M, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open. 2022;5(1): e2144178.

Article  PubMed  PubMed Central  Google Scholar